Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 625

1.

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Br J Haematol. 2019 Jul 12. doi: 10.1111/bjh.16096. [Epub ahead of print]

PMID:
31298751
2.

Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis.

Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J.

Cancer. 2019 Jun 28. doi: 10.1002/cncr.32357. [Epub ahead of print]

PMID:
31251390
3.

Impact of acquired del(17p) in multiple myeloma.

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Adv. 2019 Jul 9;3(13):1930-1938. doi: 10.1182/bloodadvances.2018028530.

4.

Multiple myeloma: Every year a new standard?

Rajkumar SV.

Hematol Oncol. 2019 Jun;37 Suppl 1:62-65. doi: 10.1002/hon.2586. Review.

PMID:
31187526
5.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
6.

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Leuk Lymphoma. 2019 May 16:1-8. doi: 10.1080/10428194.2019.1613536. [Epub ahead of print]

PMID:
31096812
7.

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.

Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2019 Apr 23;3(8):1226-1229. doi: 10.1182/bloodadvances.2019032458.

8.

MAIA under the microscope - bringing trial design into focus.

Kapoor P, Rajkumar SV.

Nat Rev Clin Oncol. 2019 Jun;16(6):339-340. doi: 10.1038/s41571-019-0198-0. No abstract available.

PMID:
30850718
9.

Natural history of multiple myeloma with de novo del(17p).

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2019 Mar 7;9(3):32. doi: 10.1038/s41408-019-0191-y.

10.

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.

Ramakrishnan VG, Miller KC, Macon EP, Kimlinger TK, Haug J, Kumar S, Gonsalves WI, Rajkumar SV, Kumar SK.

Haematologica. 2019 Mar 7. pii: haematol.2018.211110. doi: 10.3324/haematol.2018.211110. [Epub ahead of print]

11.

Two types of amyloidosis presenting in a single patient: a case series.

Sidiqi MH, McPhail ED, Theis JD, Dasari S, Vrana JA, Drosou ME, Leung N, Hayman S, Rajkumar SV, Warsame R, Ansell SM, Gertz MA, Grogan M, Dispenzieri A.

Blood Cancer J. 2019 Mar 5;9(3):30. doi: 10.1038/s41408-019-0193-9.

12.

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.

Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, Kourelis TV, Buadi FK, Kapoor P, Gonsalves W, Warsame R, Lacy MQ, Kyle RA, Rajkumar SV, Kumar SK, Leung N.

Br J Haematol. 2019 May;185(4):701-707. doi: 10.1111/bjh.15832. Epub 2019 Mar 5.

PMID:
30836444
13.

Robert A. Kyle, MD: Lessons From a Legend.

Rajkumar SV.

Mayo Clin Proc. 2019 Mar;94(3):375-376. doi: 10.1016/j.mayocp.2019.01.030. No abstract available.

PMID:
30832784
14.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma.

Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Kumar SK.

Blood Adv. 2019 Mar 12;3(5):744-750. doi: 10.1182/bloodadvances.2018022806.

15.

The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG).

Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, Dimopoulos MA, Rajkumar SV, Durie BBG, Terpos E.

Blood Cancer J. 2019 Feb 26;9(3):27. doi: 10.1038/s41408-019-0187-7.

16.

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.

Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK.

Leukemia. 2019 May;33(5):1273-1277. doi: 10.1038/s41375-019-0419-7. Epub 2019 Feb 20.

PMID:
30787429
17.

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A.

Mayo Clin Proc. 2019 Mar;94(3):472-483. doi: 10.1016/j.mayocp.2018.08.006. Epub 2019 Feb 13. Erratum in: Mayo Clin Proc. 2019 Jun;94(6):1121.

PMID:
30770096
18.

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Br J Haematol. 2019 Apr;185(2):254-260. doi: 10.1111/bjh.15800. Epub 2019 Feb 15.

PMID:
30768679
19.

Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.

Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A.

Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5. Epub 2019 Feb 8.

PMID:
30737485
20.

Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015.

Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, Rajkumar SV, Vachon CM, Dispenzieri A.

Mayo Clin Proc. 2019 Mar;94(3):465-471. doi: 10.1016/j.mayocp.2018.08.041. Epub 2019 Jan 31.

PMID:
30713046
21.

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG.

Leukemia. 2019 Jul;33(7):1736-1746. doi: 10.1038/s41375-019-0384-1. Epub 2019 Jan 29.

PMID:
30696949
22.

Smoldering Multiple Myeloma: To Treat or Not to Treat.

Kapoor P, Rajkumar SV.

Cancer J. 2019 Jan/Feb;25(1):65-71. doi: 10.1097/PPO.0000000000000350.

PMID:
30694862
23.

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 May;94(5):E117-E120. doi: 10.1002/ajh.25420. Epub 2019 Feb 6. No abstract available.

PMID:
30680770
24.

Comparative analysis of staging systems in AL amyloidosis.

Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23. No abstract available.

PMID:
30675009
25.

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Apr;94(4):424-430. doi: 10.1002/ajh.25391. Epub 2019 Jan 8.

PMID:
30592078
26.

Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.

Kumar SK, Buadi FK, Rajkumar SV.

Blood. 2019 Feb 14;133(7):652-659. doi: 10.1182/blood-2018-08-825349. Epub 2018 Dec 26. Review.

PMID:
30587528
27.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
28.

Current, Emerging, and Anticipated Therapies for Sickle Cell Disease.

Nath KA, Rajkumar SV.

Mayo Clin Proc. 2018 Dec;93(12):1703-1706. doi: 10.1016/j.mayocp.2018.10.010. No abstract available.

PMID:
30522590
29.

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV.

Blood Cancer J. 2018 Dec 11;8(12):125. doi: 10.1038/s41408-018-0163-7.

30.

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.

Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Mar;94(3):306-311. doi: 10.1002/ajh.25365. Epub 2018 Dec 13.

PMID:
30516847
31.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P.

Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.

32.

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.

Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.

33.

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.

Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV.

Blood Cancer J. 2018 Nov 15;8(12):116. doi: 10.1038/s41408-018-0140-1.

34.

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.

Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA.

Blood Cancer J. 2018 Nov 8;8(11):106. doi: 10.1038/s41408-018-0147-7.

35.

Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma.

Painuly U, Ramakrishnan V, Kimlinger T, Wellik L, Haug J, Gonsalves W, Bi L, Huang Z, Rajkumar SV, Kumar S.

Oncotarget. 2018 Oct 2;9(77):34582-34594. doi: 10.18632/oncotarget.26180. eCollection 2018 Oct 2.

36.

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Leukemia. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15.

PMID:
30323358
37.

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia.

Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P.

Leukemia. 2019 Mar;33(3):790-794. doi: 10.1038/s41375-018-0286-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315235
38.

Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry.

Baughn LB, Pearce K, Larson D, Polley MY, Elhaik E, Baird M, Colby C, Benson J, Li Z, Asmann Y, Therneau T, Cerhan JR, Vachon CM, Stewart AK, Bergsagel PL, Dispenzieri A, Kumar S, Rajkumar SV.

Blood Cancer J. 2018 Oct 10;8(10):96. doi: 10.1038/s41408-018-0132-1.

39.

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.

Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, Lentzsch S, Moreau P, Cavo M, Miguel JS, Dimopoulos MA, Rajkumar SV, Durie BGM, Terpos E, Delorme S.

Blood Cancer J. 2018 Oct 4;8(10):95. doi: 10.1038/s41408-018-0124-1.

40.

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26. No abstract available.

PMID:
30258095
41.

Value and Cost of Myeloma Therapy.

Rajkumar SV.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:662-666. doi: 10.1200/EDBK_200867. Review.

PMID:
30231405
42.

Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.

Clay-Gilmour AI, Kumar S, Rajkumar SV, Rishi A, Kyle RA, Katzmann JA, Murray DL, Norman AD, Greenberg AJ, Larson DR, O'Byrne MM, Slager SL, Vachon CM.

Leukemia. 2019 Feb;33(2):499-507. doi: 10.1038/s41375-018-0246-2. Epub 2018 Sep 10.

PMID:
30201985
43.

Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma.

Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Am J Hematol. 2018 Dec;93(12):1518-1523. doi: 10.1002/ajh.25279. Epub 2018 Oct 2.

PMID:
30194770
44.

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.

Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, Lonial S, Rajkumar SV.

Blood Cancer J. 2018 Aug 29;8(9):86. doi: 10.1038/s41408-018-0110-7.

45.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators.

N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.

46.

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.

Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ.

Blood Cancer J. 2018 Jul 30;8(8):70. doi: 10.1038/s41408-018-0106-3.

47.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9. Review.

48.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV.

Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.

49.

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.

50.

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Higgins L, Nasr SH, Said SM, Kapoor P, Dingli D, King RL, Rajkumar SV, Kyle RA, Kourelis T, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Ansell SM, Gonsalves WI, Thompson CA, Fervenza FC, Zand L, Hwa YL, Jevremovic D, Shi M, Leung N.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1037-1046. doi: 10.2215/CJN.13041117. Epub 2018 May 30.

Supplemental Content

Loading ...
Support Center